Herpes Simplex Virus Infections: Viral Infections: Merck Manual Home Edition Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
Database D D - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
Database A A - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.Abreva ™* (...
Microsoft PowerPoint - Issue 4-04.ppt Neurodex Asthma/ Allergy Abreva ® THE WAY WE THINK ABOUT DRUG DEVELOPMENT Welcome to the Avanir Pharmaceuticals newsletterAbreva ® Avanir Conference Schedule The...
author: mcruse
Microsoft PowerPoint - Issue 4-04.ppt page 2
author: mcruse
http://www.fda.gov/cder/orange/appendix_a.txt APPENDIX A PRODUCT NAME INDEX ** 0 ** 0, AMOXICILLIN ** 8 ** 8-HOUR BAYER, ASPIRIN (OTC) 8-MOP, METHOXSALEN ** A ** A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE A.P.L., GONADOTROPIN, CHORIONIC A/T/S, ERYTHROMYCIN ABELCET,...
20-941_Abreva.htm Food and Drug Administration • Center for Drug Evaluation and Research Approval Package Search Abreva (Docosanol) Cream Company:- Avanir Pharmaceuticals Application No.:- 20-941 Approval Date:-7/25/2000 - Approval Letter(s) - Printed Labeling - Medical Review(s)- Part 1 - Part 2 - Chemistry Review(s) - Pharmacology Review(s) Part 1 - Part 2 - Statistical Review(s) -...
author: Paul Stauffer
http://www.phrma.org/newmedicines/resources/2003-11-23.120.pdf T o combat the one of the world's most devastating diseases, pharmaceutical and biotechnology researchers are testing 83 medicines for HIV/ AIDS and related conditions, intensifying their efforts and achieving steady progress in the development of vaccines
http://www.phrma.org/newmedicines/resources/2003-11-23.120.pdf page 10
Approved Biotechnology Drugs, 2002 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
Report to the Nation: Drug Review Priority new drug approvals (N=NME) Abacavir/lamivudine/zidovudine (Trizivir) Alosetron (Lotronex) (N) Arsenic trioxide (Trisenox) (N) Atovaquone/proquanil (Malarone) Bexarotene (Targetin) Budesonide (Pulmicort) Didanosine (Videx EC) Gentuzumab ozogamicin (Mylotarg) (N) Levobetaxolol (Betaxon) Levofloxacin (Quixin) Linezolid (Zyvox) (3 NDAs approved, 1 as NME) (N) Lopinavir/ritonavir...
author: OLIVERN
NMEs Approved in CY 2000 NMEs Approved in Calendar Year 2000 NDA Number Generic Name- Trade Name Dosage Form Applicant - --- Classification- Approval Date 20-989 Cevimeline HCl Evoxac Capsule Snowbrand 1S 01-11-2000 21-014 Oxcarbazepine Trileptal Tablet Novartis Pharms 1S 01-14-2000 20-987 Pantoprazole Sodium Protonix Tablet Wyeth Ayerst 1S 02-02-2000 21-107 Alosetron HC1 Lotronex Tablet Glaxo Wellcome 1P 02...
author: Susan Daugherty
http://www.phrma.org/newmedicines/resources/2002-12-05.98.pdf P harmaceutical and biotechnology companies continue to research new and more effective ways to treat and prevent HIV/ AIDS, which affects an estimated 40 million people worldwide and has caused nearly half a million deaths in the United States alone
http://www.phrma.org/newmedicines/resources/2002-12-05.98.pdf page 10
BIO Editors &Reporters 03LIVE page 53
author: Elinor
http://www.phrma.org/newmedicines/resources/2001-01-10.11.pdf I n 2000, pharmaceutical and biotechnology companies received approval for 27 new drugs and 6 new biologicsAbreva AVANIR topical treatment for 12/ 22/...
http://www.phrma.org/newmedicines/resources/2001-01-10.11.pdf page 2
01-310 NewMeds AIDS Final copy A s the war against AIDS enters its third decade, pharmaceutical companies are continuing to research new weapons to thwart this persistent and deadly enemy
author: RL
01-310 NewMeds AIDS Final copy page 11
author: RL
00-322 NewMeds AIDS REV 11/17 2000 AIDS N E W M E D I C I N E S I N D E V E L O P M E N T F O R Survey P R E S E N T E D B Y A M E R I C A' S P H A R M A C E U T I C A L C O M P A N I E S P harmaceutical companies are working on the next generation of medicines for AIDS, while continuing to improve existing treatments and medicines for AIDS- related conditions, according to a new survey by the Pharmaceutical...
author: RL
00-322 NewMeds AIDS REV 11/17 page 9
author: RL
00-354 2000 PhRMA NDA 01/17 I n 2000, pharmaceutical and biotechnology companies received approval for 27 new drugs and 6 new biologicsAbreva ª AVANIR topical...
author: RL
00-354 2000 PhRMA NDA 01/17 page 2
author: RL
December 17, 2001 BioCenturyPart II VOLAbreva docosanol 10% cream, an over- the-...
author: BioCentury Publications Inc.
subject: BioCentury
December 17, 2001 page 3
author: BioCentury Publications Inc.
subject: BioCentury
